Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study on Solifenacin, Mirabegron, and Their Combination for Treating Overactive Bladder and Daytime Urinary Incontinence in Children Aged 5 to 14 Years

Fast replyRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of different treatments for children aged 5 to 14 years who have overactive bladder and daytime urinary incontinence. These conditions can cause frequent urges to urinate and accidental leakage of urine during the day. The study will explore the effectiveness of two medications, solifenacin and mirabegron, as well as a combination of both. Solifenacin is a medication that helps relax the bladder muscles, while mirabegron, also known by its code name YM178, works by helping the bladder hold more urine.

The purpose of the study is to evaluate how well these treatments work in reducing the number of wet days, which are days when accidental leakage occurs. Participants will be randomly assigned to receive either solifenacin, mirabegron, a combination of both, or a placebo. The study will last for a total of 18 weeks, with the main treatment period being 12 weeks. During this time, the number of wet days will be monitored to see how the treatments are working. The study will also look at other factors, such as changes in the severity of incontinence and the amount of urine the bladder can hold.

Throughout the study, participants will have regular check-ups to monitor their progress and any side effects. The study aims to provide valuable information on the best treatment options for children with overactive bladder and daytime urinary incontinence, potentially improving their quality of life. Participants will be closely monitored to ensure their safety and well-being during the trial.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    The participant's legal guardian must sign an informed consent form before any study-specific procedures begin.

    The participant must be between 5 and 14 years old and have an overactive bladder with at least two daytime urinary incontinence episodes per week.

    The participant should have had inadequate results from four weeks of non-drug treatment and no prior treatment with the study medications.

  2. Step 2

    Initial assessment

    An initial assessment will be conducted to confirm eligibility and establish baseline measurements.

    The participant's ability to swallow the study medication will be evaluated.

  3. Step 3

    Medication administration

    The participant will receive one of the following treatments: solifenacin, mirabegron, or a combination of both.

    Solifenacin is provided as a film-coated tablet, and mirabegron as a prolonged-release tablet, both taken orally.

    The treatment period lasts for 12 weeks, during which the participant's response to the medication will be monitored.

  4. Step 4

    Monitoring and evaluation

    The primary outcome is the reduction in the number of wet days per week, assessed every 7 days using a tool called DryPie.

    Secondary outcomes include changes in incontinence severity, urge severity, and other bladder function metrics over an 18-week period.

    Regular monitoring for any adverse events or unexpected reactions will occur throughout the study.

  5. Step 5

    Final assessment

    At the end of the treatment period, a final assessment will be conducted to evaluate the overall treatment response.

    The participant's progress will be compared to baseline measurements to determine the effectiveness of the treatment.

Who can join the trial?

8 criteria

  • The person responsible for the child must willingly sign a form agreeing to participate in the study before any study-related activities begin.
  • The child must be between the ages of 5 and 14 years old when the consent form is signed.
  • The child must have an overactive bladder, which means the bladder muscles contract too often, causing a sudden need to urinate.
  • The child must have at least 2 episodes of daytime urinary incontinence per week. This means the child has trouble controlling their bladder during the day.
  • The child must have tried urotherapy for at least 4 weeks without enough improvement. Urotherapy is a non-drug treatment that includes exercises and lifestyle changes to help with bladder control.
  • The child must not have been treated before with solifenacin, mirabegron, or injections of botulinum toxin into the bladder muscle.
  • The child must not currently have constipation, which is difficulty in having bowel movements, according to specific medical guidelines called ROME IV, or fecal incontinence, which is trouble controlling bowel movements. However, using laxatives to help with bowel movements is allowed.
  • The child must be able to swallow or be able to learn how to swallow the study medication, according to the doctor's opinion.

Who cannot join the trial?

3 criteria

  • Children younger than 5 years old cannot participate.
  • Children older than 14 years old cannot participate.
  • Children who do not have **daytime urinary incontinence** or an **overactive bladder** cannot participate. **Daytime urinary incontinence** means having trouble controlling the bladder during the day. **Overactive bladder** means feeling a sudden urge to urinate that is hard to control.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Solifenacin is a medication used to help control an overactive bladder. It works by relaxing the bladder muscles, which can help reduce the urge to urinate frequently and prevent accidents. Mirabegron is another medication that helps manage an overactive bladder. It works differently from solifenacin by activating certain receptors in the bladder, which helps the bladder hold more urine and reduces the need to urinate urgently. The combination therapy of Solifenacin and Mirabegron involves using both medications together. This approach aims to provide a more effective treatment for children with overactive bladder and daytime urinary incontinence by combining the benefits of both medications.

What is already known about the treatment

  • Solifenacin

    Solifenacin is administered orally in tablet form and is currently being studied for its effectiveness in treating daytime urinary incontinence and overactive bladder in children. It is well-documented in medical literature as a treatment for overactive bladder in adults, and its use in children is under investigation. The medication works by blocking specific receptors in the bladder, reducing muscle contractions and increasing bladder capacity. It is classified as an antimuscarinic agent.

  • Mirabegron

    Mirabegron is taken orally in tablet form and is being evaluated for its role in managing daytime urinary incontinence and overactive bladder in children. It is already established in medical practice for adults with similar conditions. The drug functions by stimulating certain receptors in the bladder, which helps relax the bladder muscle and improve storage capacity. Mirabegron is classified as a beta-3 adrenergic agonist.

Investigated diseases

  • Daytime Urinary Incontinence

    This condition involves the involuntary leakage of urine during the day. It can occur due to various reasons, including an overactive bladder, which causes a sudden and intense urge to urinate. The bladder muscles may contract involuntarily, leading to urine leakage. This condition is more common in children and can affect their daily activities and social interactions. It may be associated with frequent urination and the inability to hold urine for long periods. Over time, it can impact a child's confidence and quality of life if not managed properly.

  • Overactive Bladder

    This condition is characterized by a frequent and sudden urge to urinate that is difficult to control. It may lead to involuntary loss of urine, known as urge incontinence. The bladder muscles contract more often than normal, even when the bladder is not full. This can result in frequent trips to the bathroom, both during the day and at night. The condition can affect people of all ages but is more common in older adults. It can significantly impact daily life and activities due to the constant need to find a restroom.

Trial detailsLast updated 2 Oct 2026
Age0-17PhasePhase IIITrial ID2023-510187-13-00Protocol codeBeDry-2023Estimated enrolment236 patientsSponsorRegion Midtjylland

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).